ClinicalTrials.gg
CompletedNCT02714322Updated Mar 11, 2022

MYL-1401A Efficacy and Safety Comparability Study to Humira®

A Phase 3 interventional study of MYL-1401A (Adalimumab) and Humira® (Adalimumab) in Psoriasis and Arthritis, Psoriatic, sponsored by Mylan Inc.. Completed at 33 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-11.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mylan Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing adalimumab in Arthritis, Psoriatic — 5 open to participants now, 5 under way, 2 of them phase 3. Adalimumab · Arthritis, Psoriatic.

Enrollment
2nd of 13
294 · median 108
Started
2015
the only one that year
Phase 3
5 of 13
2 open now
Registered
5th of 13
by date
Lead sponsor
1 of 13
Mylan Inc.

Among the 13 studies testing adalimumab in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 5 in phase 3, and was the 5th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 13 studies testing adalimumab in Arthritis, Psoriatic are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing adalimumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

To assess the equivalence of MYL-1401A to Humira® with regards to efficacy in subjects with moderate-to-severe chronic plaque psoriasis

Read the detailed description

Eligible subjects will be randomly assigned based on predefined stratification factors of weight, geographic region, and presence of psoriatic arthritis:

Randomization is 2:1 to MYL-1401A or Humira®, respectively.

The study will be conducted in the outpatient setting and comprises 3 periods: a screening period of up to 4 weeks, a 52-week treatment period, and a safety follow-up for 8 weeks.

A subject will be considered to have completed the study once they have completed the 52-week treatment period and the 8-week follow-up visit.

03

Conditions studied

  • Psoriasis
  • Arthritis, Psoriatic

Browse trials for

Keywords

  • Adalimumab
  • Biologics
  • Biosimilar
04

In context

Arthritis, Psoriatic Reclassified

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

This study's enrollment of 294 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Mylan Inc. is the lead sponsor of 44 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.

First submitted before Mylan Inc. became part of Viatris Inc..

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has signed the form
  2. Subject is aged 18 to 75 years, inclusive, at time of Screening
  3. Subject has had moderate-to-severe chronic plaque psoriasis for at least 6 months

    • Subject has involved BSA ≥10%, PASI ≥12, and sPGA ≥3 (moderate) at Screening and at Baseline
  4. Subject has had stable disease for at least 2 months (i.e. without significant changes as defined by the investigator)
  5. Subject is a candidate for systemic therapy
  6. Subject has had a previous failure, inadequate response, intolerance, or to at least 1 conventional antipsoriatic systemic therapy
  7. Subject is naïve to adalimumab therapy, approved or
  8. For females of , a negative serum pregnancy test during Screening and a negative urine pregnancy test at Baseline

Exclusion criteria

Exclusion Criteria:

  1. Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (e.g. eczema), or other systemic disorder inflammatory disease at the time of the screening visit that would interfere with evaluations of the effect of the study treatment on psoriasis
  2. Subject has used any of the following medications within specified time periods or will require their use during the study:

    • Topical medications within 2 weeks before the end of the screening period
    • oral psoralen with ultraviolet A (PUVA) phototherapy and/or ultraviolet B (UVB) phototherapy within 4 weeks before the end of the screening period
    • Nonbiologic systemic therapies within 4 weeks before the end of the screening period (e.g. cyclosporine, methotrexate, and acitretin)
    • Any prior or concomitant adalimumab therapy, approved or
    • Any other investigational agent within 90 days or 5 half-lives of Screening (whichever is longer)
    • Any systemic in the 4 weeks before the end of the screening period Note: Low-potency topical corticosteroids applied to the palms, soles, face, and intertriginous areas are permitted during study participation
  3. Subject has received during the 4 weeks prior to Screening or has the intention of receiving a live vaccine at any time during the study
  4. Subject has a positive test for tuberculosis (TB) during Screening or a known history of active or latent TB, except documented and complete adequate treatment of TB or initiation (>1 month) of adequate prophylaxis of latent TB, with an isoniazid-based regimen

    • Subjects with a positive purified protein derivative (PPD) and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative Interferon-γ release assays (IGRA)
    • Subjects with a positive PPD test without a history of Bacillus Calmette-Guérin vaccination or subjects with a positive or indeterminate IGRA are allowed if they have all of the following:
    • No symptoms or signs of active TB, including a negative chest x-ray within 3 months prior to the first dose of study treatment
    • Documented history of completion of adequate treatment of TB or initiation (>1 month) of adequate prophylaxis of latent TB, with an isoniazid-based regimen prior to receiving study treatment in accordance with local recommendations
  5. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal) which, in the opinion of the investigator, significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy
  6. Subject has a planned surgical intervention during the duration of the study except those related to the underlying disease and which, in the opinion of the investigator, will not put the subject at further risk or hinder the subject's ability to maintain compliance with study treatment and the visit schedule
  7. Subject has an active and serious infection or history of infections as follows:

    • Any active infection:
    • For which nonsystemic anti-infectives were used within 4 weeks prior to randomization.
    • Requiring hospitalization or systemic anti-infectives within 8 weeks prior to randomization
    • Recurrent or chronic infections or other active infection that, in the opinion of the investigator, might cause this study to be detrimental to the subject
    • Invasive fungal infection or mycobacterial infection
    • Opportunistic infections, such as listeriosis, legionellosis, or pneumocystis
  8. Subject is positive for , virus antibody or surface antigen (HBsAg) or is positive for hepatitis B core antibody and negative for HBsAg at Screening
  9. Subject has a history of hematological abnormalities, including cytopenias (e.g. thrombocytopenia, leukopenia)
  10. Subject has severe progressive or uncontrolled, clinically significant disease that in the judgment of the investigator renders the subject unsuitable for the study
  11. Subject has history of within 5 years except adequately treated cutaneous squamous or basal cell carcinoma, in situ cervical cancer or in situ breast ductal carcinoma
  12. Subject has active neurological disease such as multiple sclerosis, Guillain-Barré syndrome, optic neuritis, transverse myelitis, or history of neurologic symptoms suggestive of central nervous system demyelinating disease
  13. Subject has moderate-to-severe heart failure ( class III/IV)
  14. Subject has a history of to the active substance or to any of the of Humira® or MYL-1401A
  15. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation
  16. Evidence of alcohol or drug abuse or dependency at the time of Screening, for the 5 years prior to Screening or during the study
  17. Subject is unable to follow study instructions and comply with the protocol in the opinion of the investigator
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
294 participants (actual)

Study arms

  • Experimental
    MYL-1401A (Adalimumab)

    MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose

    Biological: MYL-1401A (Adalimumab)

  • Active comparator
    Humira® (Adalimumab)

    Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose

    Biological: Humira® (Adalimumab)

Interventions

  • MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose

  • Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose

07

What researchers measure

Primary outcomes

  1. Percent improvement in PASI from Baseline

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Proportion of subjects showing at least a 75% improvement in PASI (PASI 75 response rate)

    Time frame: Week 12

  2. Number of subjects achieving static Physician's Global Assessment (sPGA) responses of clear (0) or almost clear (1)

    Time frame: Week 12

08

Study locations

33 sites
  • Mylan Investigational Site 102
    Plovdiv, Bulgaria
  • Mylan Investigational Site 105
    Plovdiv, Bulgaria
  • Mylan Investigational Site 101
    Sevlievo, Bulgaria
  • Mylan Investigational Site 100
    Sofia, Bulgaria
  • Mylan Investigational Site 103
    Sofia, Bulgaria
  • Mylan Investigational Site 107
    Tallinn, Estonia
  • Mylan Investigational Site 108
    Tallinn, Estonia
  • Mylan Investigational Site 109
    Tallinn, Estonia
  • Mylan Investigational site 110
    Tallinn, Estonia
  • Mylan Investigational Site 106
    Tartu, Estonia
  • Mylan Investigational SIte 112
    Tartu, Estonia
  • Mylan Investigational Site 127
    Budapest, Hungary
  • Mylan Investigational Site 128
    Budapest, Hungary
  • Mylan Investigational Site 125
    Debrecen, Hungary
  • Mylan Investigational Site 129
    Gyula, Hungary
  • Mylan Investigational Site 126
    Szekszárd, Hungary
  • Mylan Investigational Site 131
    Bialystok, Poland
  • Mylan Investigational Site 137
    Bialystok, Poland
  • Mylan Investigational Site 135
    Iwonicz-Zdroj, Poland
  • Mylan Investigational Site 140
    Krakow, Poland
  • Mylan Investigational Site 139
    Lodz, Poland
  • Mylan Investigational Site 133
    Olsztyn, Poland
  • Mylan Investigational Site 138
    Poznan, Poland
  • Mylan Investigational Site 136
    Warsaw, Poland
  • Mylan Investigational Site 130
    Wroclaw, Poland
  • Mylan Investigational Site 132
    Wroclaw, Poland
  • Mylan Investigational Site 134
    Wroclaw, Poland
  • Mylan investigational site 156
    Kazan, Russian Federation
  • Mylan Investigational site 155
    Penza, Russian Federation
  • Mylan Investigational Site 148
    Ryazan, Russian Federation
  • Mylan Investigational Site 149
    St. Petersburg, Russian Federation
  • Mylan Investigational site 159
    Kharkiv, Ukraine
  • Mylan investigational site 161
    Uzhhorod, Ukraine
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of May 2016 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2015
First posted
Mar 21, 2016
Start
Jun 2015
Primary completionActual
May 2016
CompletionActual
Mar 2017
Last update
Mar 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02714322
Lead sponsor
Mylan Inc.
Collaborators
Mylan GmbH
Responsible party
Sponsor
First posted
Mar 21, 2016
Start date
Jun 2015
Primary completion
May 2016
Completion
Mar 2017
Last update
Mar 11, 2022

Study contacts

Abhijit Barve, MD
study chair · Mylan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion